Core Insights - MKS Inc. operates in the technology sector, providing instruments, subsystems, and process control solutions across various industries, including semiconductor and life sciences [1] Insider Activity - Gerald G. Colella, a director at MKS Inc., sold 10,000 shares at approximately $253.97 each, retaining 40,017 shares post-sale [2] - John Edward Williams, Executive Vice President, sold 2,043 shares at an average price of $256.41, resulting in a 35.95% decrease in his ownership, leaving him with 3,640 shares valued at around $933,332 [3] Stock Performance - MKS Inc.'s stock opened at $253.71 with a market capitalization of $17.04 billion and a P/E ratio of 58.06, indicating high investor valuation [4] - The stock has a beta of 1.94, suggesting it is more volatile than the market [4] Financial Health - The company has a debt-to-equity ratio of 1.53, a current ratio of 2.71, and a quick ratio of 1.71, indicating its ability to meet short-term obligations [5] - The fifty-day moving average is $206.74, while the two-hundred-day moving average is $157.93, showing an upward trend over time [5]

Company Overview - ASA Gold and Precious Metals Limited focuses on investing in gold and other precious metals, operating as a closed-end fund that provides investors with exposure to the precious metals sector [1] Insider Activity - On February 20, 2026, COO Merk Alexander sold 13,155 shares at $70.60 each, indicating potential insider sentiment that could influence investor confidence [2][6] - Major shareholder Saba Capital Management has been actively increasing its stake in ASA, purchasing 50,560 shares at an average price of $71.50 per share on February 13, totaling $3.6 million, which increased their position by 0.86% [3] - On February 12, Saba Capital Management acquired an additional 83,533 shares at an average price of $69.69 per share, amounting to $5.8 million, representing a 1.45% increase in their position [4] Stock Performance - ASA's stock is currently trading at $72.66, reflecting a 3.68% increase with a price change of $2.58, and has fluctuated between $69.91 and $73.81 during the day [5][6] - Over the past year, ASA has seen a high of $78.21 and a low of $23.93, with a market capitalization of approximately $1.37 billion and a trading volume of 137,650 shares [5][6]

Core Viewpoint - Atle Fund Management AB increased its holdings in Gilead Sciences by 6.8% in Q3, indicating growing institutional interest in the biopharmaceutical company [2] Institutional Holdings - Norges Bank acquired a new stake in Gilead valued at approximately $2.15 billion in Q2 - Ameriprise Financial increased its stake by 397.6% in Q2, now owning 6,748,403 shares valued at $748.15 million after purchasing an additional 5,392,191 shares - Invesco Ltd. raised its position by 33.5% in Q2, now holding 13,521,228 shares worth $1.50 billion after buying 3,394,330 shares - Assenagon Asset Management increased its holdings by 164.4% in Q3, now owning 3,489,062 shares valued at $387.29 million after acquiring 2,169,266 shares - Vanguard Group lifted its stake by 1.6% in Q2, now owning 119,364,226 shares worth $13.23 billion after acquiring 1,893,401 shares - Institutional investors and hedge funds currently own 83.67% of Gilead's stock [3] Stock Performance - Gilead Sciences shares opened at $141.95, with a market cap of $176.11 billion - The stock has a price-to-earnings ratio of 22.01, a PEG ratio of 0.73, and a beta of 0.33 - The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45, and a quick ratio of 1.31 - The one-year low for the stock is $93.37, and the one-year high is $142.20 [4] Earnings Results - Gilead reported an EPS of $2.47 for the latest quarter, exceeding the consensus estimate of $2.16 by $0.31 - The company achieved a net margin of 27.88% and a return on equity of 51.86% - Quarterly revenue was $7.77 billion, surpassing the consensus estimate of $7.42 billion, and up 3.0% year-over-year - Analysts expect Gilead to post an EPS of 7.95 for the current year [5] Analyst Ratings - Leerink Partners raised their price target from $114.00 to $146.00, rating the stock as "outperform" - Rothschild & Co Redburn increased their target from $153.00 to $159.00 with a "buy" rating - Sanford C. Bernstein set a price objective of $135.00 with an "outperform" rating - Citigroup raised their target from $140.00 to $156.00 with a "buy" rating - HSBC lifted their target from $110.00 to $133.00 with a "hold" rating - The stock has a consensus rating of "Moderate Buy" with an average target price of $136.73 [6] Insider Activity - Director Kelly A. Kramer sold 2,805 shares at an average price of $127.10, totaling $356,515.50, reducing ownership by 67.69% - CFO Andrew D. Dickinson sold 3,000 shares at an average price of $124.31, totaling $372,930.00, a 1.95% decrease in ownership - Over the last 90 days, insiders sold 257,397 shares worth $33.39 million, with insiders owning 0.27% of the company's stock [8] Company Overview - Gilead Sciences, founded in 1987 and headquartered in Foster City, California, focuses on developing medicines for high unmet medical needs - The company is known for its antiviral therapies and has expanded into oncology, cell therapy, and inflammatory diseases [9][10]